Keynatinib
Phase 1Small molecule
Keynatinib is one of 18 small molecule programs targeting Lymphoma, B-Cell. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Lymphoma, B-Cell
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 1
Adriamycin
PfizerPhase 1
Oncovin
Eli LillyPhase 1
Venclexta
AbbViePhase 1
Gemzar
Johnson & JohnsonPhase 1
COLUMVI
RochePhase 1
Polivy
RochePhase 1
Cytoxan
BBaxter Healthcare Corporation
Phase 1
Rayos
RRoxane Laboratories
Phase 1
Decadron
AAspen Global Incorporated
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Keynatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMedolution Ltd.